Bristol-Myers Squibb (NYSE: BMY) has sent a letter to Imclone Systems (NASDAQ: IMCL) in response to yesterday’s rejection of its buyout offer. It said it is disappointed that the $60.00 bid was…
Douglas A. McIntyre ImClone Systems Inc. (NASDAQ: IMCL) is a biotech buyout bonanza stock that traders and investors have been watching closely. The company has said that the proposed $60.00 per share cash buyout from…
Douglas A. McIntyre According to Reuters, large Yahoo! (YHOO) holder Capital Research want to know whether vote counts from the company’s annula meeting were accurate. Reuters writes that the Fed is seen as holding rates…
Carl Icahn and friends at ImClone Systems Incorporated (NASDAQ: IMCL) have now formally responded to Bristol-Myers Squibb Company (NYSE: BMY) regarding the cash buyout of the company. The company’s board of directors…
Douglas A. McIntyre According to Reuters, GM (GM) is expected to post a huge loss. Reuters reports that oil company profits rose, but Exxon (XOM) missed its numbers. Reuters reported that stressed banks borrowed a…
Another biotech giant is biting the dust via a buyout offer. ImClone Systems Inc. (NASDAQ: IMCL) has been given a buyout offer from Bristol-Myers (NYSE: BMY) at $60.00 per share. As per…
Douglas A. McIntyre ImClone Systems Incorporated (NASDAQ: IMCL) has just announced that ERBITUX(R) has received marketing authorization in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC). This approval will allow…
Douglas A. McIntyre If you thought this was a bad day for the market with the DJIA trading well under that 12,000 psychological level, there were some 400 stocks that hit 52-week lows today when…
These are ten of the analyst calls we are focusing on this Wednesday morning in pre-market trading: Bristol-Myers (NYSE: BMY) cut to Neutral at Cowen. Marriott (NYSE: MAR) cut to Perform at…
Bristol-Myers Squibb (NYSE: BMY) has submitted an open shelf offering today for an undetermined amount. The offering includes a combination of debt securities, preferred stock, depositary shares, common stock, and warrants to…
Douglas A. McIntyre Bristol-Myers Squibb Company (NYSE: BMY) came out with earnings at $0.35 EPS and reaffirmed 2008 guidance of $1.36 to $1.46 GAAP EPS and $1.60 to $1.70 non-GAAP EPS. It also maintained a…
Douglas A. McIntyre Medarex, Inc. (NASDAQ: MEDX) wants to clarify a few issues regarding the study halt from Pfizer (NYSE: PFE) this week on advanced melanoma. The company says that there are key differences between…
Bristol-Myers (NYSE: BMY) does not see much future in baby food. It is trying to sell its operation to a company where its is a better fit. According to the FT, that…
Those rummaging through the garbage of 52-week low lists are usually bottom-fishing investors or desperate CEOs. But, the list is so broad that it has become a tableau of the market as…
Some large companies, like Bristol-Myers (BMY), has already said that auction-rate securities on their balance sheets may have to be written down now that the market for this paper is illiquid. The…
Douglas A. McIntyre